We are live on ! Find out more
KROS icon

Keros Therapeutics

148 hedge funds and large institutions have $2.08B invested in Keros Therapeutics in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 40 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

280% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 10

172% more capital inflows, than outflows

Capital inflows: $534M | Capital outflows: $196M

68% more call options, than puts

Call options by funds: $4.81M | Put options by funds: $2.86M

43% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 40

22% more funds holding

Funds holding: 121 → 148 (+27)

1.31% more ownership

Funds ownership: 85.94% → 87.26% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
148
Holders Change
+27
Holders Change %
+22.31%
% of All Funds
2.12%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
38
Increased
57
Reduced
40
Closed
10
Calls
$4.81​M
Puts
$2.86​M
Net Calls
+$1.95​M
Net Calls Change
+$684​K

KROS Hedge Fund Activity: Q1 2024 in Review

148 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2024, worth a combined $2.08B — up 103% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new KROS positions and 10 closed out — a net gain of 28 holders — while 57 added to existing stakes and 40 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $67.9M. The largest seller was Morgan Stanley, cutting an estimated $37.7M.

  • 148 institutional investors held Keros Therapeutics (KROS) as of Q1 2024, up from 121 in Q4 2023.
  • Funds reported $2.08B of Keros Therapeutics stock for Q1 2024, up 103% quarter-over-quarter.
  • 38 funds opened new Keros Therapeutics positions in Q1 2024 and 10 closed out, a net change of +28 holders.
  • The largest Keros Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $67.9M added.
  • The largest Keros Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $37.7M sold.

Based on aggregated 13F filings for Q1 2024.